EUVIMEDEUVIMED entdecken
Crossref

Establishment of a Novel Anti-EphA4 Monoclonal Antibody, Ea 4 Mab-3, for Versatile Applications

Ayano Saga, Guanjie Li, Tomohiro Tanaka, Mika K Kaneko, Hiroyuki Suzuki, Yukinari Kato iD

Monoclonal Antibodies in Immunodiagnosis & Immunotherapy · 2026-08 · 45 (4) · 48-57

DOI: 10.1177/21679436261450334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Monoclonal Antibodies in Immunodiagnosis & Immunotherapy, online erschienen am 23.05.2026. Verfasst von Ayano Saga und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Receptor, EphA4, Carcinoma, Squamous Cell. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Erythropoietin-producing hepatocellular carcinoma (Eph) receptor A4 (EphA4) binds to a broad range of ephrin ligands and is upregulated in various tumors. EphA4 activation plays crucial roles in the maintenance of cancer invasiveness, immune evasion, and stem cell properties. Furthermore, a novel EphA4 ligand, secretory ribonuclease 1, has been identified, and its interaction stimulates EphA4 signaling, leading to the promotion of cancer stem cell properties. Therefore, EphA4 has been considered an attractive target for cancer therapies. Thus, monoclonal antibodies (mAbs) against EphA4 are essential for basic research and mAb-based treatment in the clinic. In this study, we developed a novel anti-human EphA4 mAb, Ea 4 Mab-3, using the Cell-Based Immunization and Screening (CBIS) method. Ea 4 Mab-3 reacted with EphA4-overexpressed Chinese hamster ovary-K1 (CHO/EphA4) and endogenous EphA4-positive lung squamous cell carcinoma LK-2 in flow cytometry. The binding affinities (apparent dissociation constant K D values) were determined as 4.5 × 10 −9 M for CHO/EphA4 and 2.5 × 10 −9 M for LK-2. Furthermore, Ea 4 Mab-3 did not exhibit cross-reactivity with other Eph receptor-overexpressed CHO-K1 cells. In addition, Ea 4 Mab-3 is suitable for immunoblotting and immunohistochemistry. These results indicate that Ea 4 Mab-3, established using the CBIS method, facilitates basic studies of EphA4 and is expected to be useful for mAb-based tumor diagnosis and therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalReceptor, EphA4Carcinoma, Squamous CellAnimalsHumansCHO CellsCricetulusMiceCricetinaeCell Line, TumorFlow Cytometry

Stichwörter der Autor:innen

CBIS methodEphA4flow cytometryimmunohistochemistrymonoclonal antibody

Substanzen

Antibodies, MonoclonalReceptor, EphA4

Autor:innen und Institutionen

  • Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.

ORCID-Profile: Yukinari Kato

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Saga, A., Li, G., Tanaka, T., Kaneko, M. K., Suzuki, H., & Kato, Y. (2026). Establishment of a Novel Anti-EphA4 Monoclonal Antibody, Ea 4 Mab-3, for Versatile Applications. Monoclonal Antibodies in Immunodiagnosis & Immunotherapy, 45(4), 48-57. https://doi.org/10.1177/21679436261450334

Vancouver

Saga A, Li G, Tanaka T, Kaneko MK, Suzuki H, Kato Y. Establishment of a Novel Anti-EphA4 Monoclonal Antibody, Ea 4 Mab-3, for Versatile Applications. Monoclonal Antibodies in Immunodiagnosis & Immunotherapy. 2026;45(4):48-57. doi:10.1177/21679436261450334

BibTeX
@article{Saga2026,
  author = {Saga, Ayano and Li, Guanjie and Tanaka, Tomohiro and Kaneko, Mika K and Suzuki, Hiroyuki and Kato, Yukinari},
  title = {Establishment of a Novel Anti-EphA4 Monoclonal Antibody, Ea 4 Mab-3, for Versatile Applications},
  journal = {Monoclonal Antibodies in Immunodiagnosis & Immunotherapy},
  year = {2026},
  volume = {45},
  number = {4},
  pages = {48--57},
  doi = {10.1177/21679436261450334}
}
Kostenlos starten →